<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107054</url>
  </required_header>
  <id_info>
    <org_study_id>A7881014</org_study_id>
    <nct_id>NCT01107054</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers</brief_title>
  <official_title>A Double Blind, Randomized, Multiple Dose, Placebo And Active Controlled 4-Way Crossover Study To Investigate The Effects Of Inhaled PF-00610355 On QT/QTC Interval In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess whether multiple dose administration of PF00610335 has the potential to affect QTc in healthy volunteers</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of a positive control (moxifloxacin) on QTc interval in healthy volunteers</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To asses the the relationship between plasma concentrations of PF00610335 and its effects, if any on the QTc interval</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Pulmonary Disease</condition>
  <condition>Lung Disease</condition>
  <condition>Moxifloxacin</condition>
  <arm_group>
    <arm_group_label>PF-00610355 450 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An orally inhaled dose of PF-00610355 450 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-00610355 1200 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An orally inhaled dose of PF-00610355 1200 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single oral dose of moxifloxacin 400 mg on Day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single oral dose of non-matched placebo on Day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00610355</intervention_name>
    <description>An orally inhaled dose of PF-00610355 450 µg on days 1 to 4</description>
    <arm_group_label>PF-00610355 450 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00610355</intervention_name>
    <description>An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4</description>
    <arm_group_label>PF-00610355 1200 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>A single oral dose of moxifloxacin 400 mg on Day 4.</description>
    <arm_group_label>moxifloxacin 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A single oral dose of non-matched placebo on Day 4.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects aged 18 to 55 years

          -  Informed consent document signed by the subject or a legally acceptable representative

          -  Subjects who are willing and able to comply with the scheduled visits, treatment
             tests, laboratory tests, and other study procedures

        Exclusion Criteria:

          -  Evidence or history of clinically significant haematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic psychiatric, neurologic or
             allergic disease or clinical findings at screening

          -  Conditions possibly affecting drug absorption

          -  12-lead ECg demonstrating QTc &gt; 450ms or any other clinically significant
             abnormalities at screen

          -  Positive urine drug screen

          -  Hypersensitivity to moxifloxacin or PF00610335

          -  Unwilling or unable to comply with the lifestyle guidelines in the protocol Treatment
             with an investigational drug within 3 months or 5 half lives (whichever is longer)
             preceding the first dose of study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7881014&amp;StudyName=A%20Study%20to%20investigate%20the%20effects%20of%20PF00610335%20on%20the%20QT/QTC%20interval%20in%20healthy%20volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>January 12, 2011</last_update_submitted>
  <last_update_submitted_qc>January 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>QTC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

